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The anti-atherogenic effect of HDL has been suggested to be partly due to the action of HDL-associated paraoxonase (PON). Three
distinct enzymes have been identified, encoded by PON1, PON2 and PON3, clustered on chromosome 7q21–q22. Two cSNPs in PON1
(L55M and Q192R) and one in PON2 (S311C) have been implicated as independent risk factors for coronary heart disease (CHD) in some,
but not all, studies. A PON3 SNP (A99A) was identified and the effect of these four PON SNPs on HDL levels and CHD risk was examined
in the prospective Northwick Park Heart Study II (NPHSII). Genotype frequencies did not differ between cases and controls but the CHD risk
associated with smoking was significantly modified by PON1 L55M genotype. Compared to LL non-smokers, LL smokers had a hazard ratio
(HR) of 1.30 (95% CI 0.81–2.06) while M-allele carriers had a HR of 1.76 (1.17–2.67). When genotypes were analysed in combination,
men with the genotype PON1 55 LM/MM+PON2 311 CC, had HR of 3.54 (1.81–6.93) compared to PON1 LL+PON2 SS/SC men
(interaction P= 0.004). These effects were independent of classical risk factors. These data demonstrate the importance of stratifying by
environmental factors and the use of multiple SNPs for genetic analysis.
D 2003 Elsevier B.V. All rights reserved.Keywords: Paraoxonase; Polymorphism; PON1; PON2; PON31. Introduction
Human serum paraoxonase (PON1) is a 44-kDa glyco-
protein [1] located almost exclusively on apolipoprotein
(apo) AI and apoJ containing high-density lipoprotein
(HDL) [2]. HDL levels are inversely proportional to the
risk of coronary heart disease (CHD) (reviewed in Ref. [3]),
and HDL has been shown to prevent the oxidative modifi-
cation of low-density lipoprotein (LDL) in vivo and in vitro
[4]. This anti-oxidative property has been attributed to
serum PON [5,6], which also inhibits modification of
HDL by lipid peroxidation [7]. These anti-oxidant proper-
ties have been confirmed in mouse models, with pon1
knockout mice being more susceptible to developing ath-0925-4439/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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1 These two authors contributed equally to the paper.erosclerotic lesions than their littermates [8], in a dose
dependent manner [9].
PON1 is a member of a multigene family, which includes
PON2 and PON3 [10]. The gene cluster maps to chromo-
some 7q21–q22 [11] and covers approximately 136kb.
Several PON1 SNPs have been identified, among them
L55M and Q192R. The Q192R ‘activity’ polymorphism
[11] is so called because of the eightfold increase in
hydrolysis activity toward paraoxon demonstrated by the
R allele; this activity is substrate-dependent with the Q
isoform showing greater activity against nerve gases such as
soman and sarin [12]. Both the Q192R and L55M poly-
morphisms have been associated with CHD in some
[13,14], but not all, studies [15,16]. PON1 levels are lower
in patients suffering a myocardial infarction (MI) [17], in
patients with familial hypercholesteraemia (FH) and insulin-
dependent diabetes [18], suggesting an important role for
serum PON in CHD. PON1 levels and activity vary mark-
edly between individuals (10–30-fold) [12] as well as
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the reason for lack of clarity on this matter.
Several variants of PON2 have also been reported, with
almost complete allelic association between an A148G
change and a C311S change [20]. The presence of the C
allele of S311C variant has been associated with an inde-
pendent protective effect in FH patients [21], and in an
Asian–Indian study [22], but not in a Japanese study [23].
The PON2 S311C variant has also been shown to interact
with PON1 Q192R in an additive manner in determining
CHD risk [22]. The third PON gene (PON3) has, as yet, no
confirmed coding region polymorphisms but a recent report
[24] identified a  133C>A polymorphism in the promoter
region which was not found to be associated with a
significant effect on CHD risk.
The purpose of the present study was to examine in a
large prospective study the previously reported associations
of the PON gene cluster polymorphisms, specifically the
combined effect of PON1 and PON2 genotypes on CHD
risk and to identify and evaluate the effect of PON3 variants.
The fact that smoking reduces PON1 activity directly [25]
suggests PON1 may play an important role in smoking-
associated risk of CHD; thus, an additional aim of this study
was to examine whether the PON cluster polymorphisms
modified the smoking-associated risk of CHD.2. Methods
2.1. Subjects
Three thousand and fifty two (3052) healthy men aged
50 to 61 years, registered with nine general medical
practices, were recruited for prospective surveillance. The
methods used have been described previously [26]. Briefly,
all were free of a history of unstable angina, myocardial
infarction or evidence of a silent infarction, coronary
surgery, aspirin or anticoagulant therapy, cardiovascular
disease, malignancy (except skin cancer other than mela-
noma), or any condition precluding informed consent.
Each participant attended non-fasting, having been in-
structed to avoid heavy meals before examination and to
refrain from smoking or vigorous exercise from the pre-
ceding midnight. Each answered a questionnaire for smok-
ing habit [27]. A smoker was defined as any man who had
smoked at least one cigarette/day on average for a year or
more. Those smokers who had not smoked to this extent in
the previous year were categorised as ex-smokers; all other
men were classified as never-smokers. Smoking question-
naires were completed at baseline and annually to year 5.
Alcohol consumption was assessed by questionnaire, and
stratified according to WHO guidelines as those who
consumed more or less than 21 units/week. A standard
12-lead electrocardiogram (ECG) was recorded and coded
according to Minnesota criteria [28] (42 men with changes
indicative of myocardial infarction (codes 11, 12.1, to 12.7or 12.8 plus 51 or 52) were excluded from the study).
Height (m) was measured on a stadiometer and weight
(kg) on a balance scale to calculate body mass index
(BMI, kg/m2). Survivors have been re-called annually for
interview and repeat measurements. A routine ECG was
repeated at the sixth examination. The study had ethical
approval from the local MRC institutional review commit-
tee and patients gave written, informed consent. To date,
there have been 205 documented CHD events, in the
subjects with DNA available for analysis (fatal + non-fatal
MI = 147, need for CABG= 39, ECG ischaemia = 19).
2.2. Plasma measures
A 5-ml sample of venous blood was taken by Vacutainer
technique (Becton Dickenson, Cowley, Oxford) into a glass
tube. Serum was transferred to plastic screw-cap vials
(Nunc) and stored at  40 jC pending analysis. Cholesterol
and triglyceride concentrations were determined by auto-
mated enzyme procedures with reagents from Sigma (Poole,
Dorset, UK) and Wako Chemicals (Alpha Laboratories,
Eastleigh, UK), respectively. Serum apolipoprotein AI
(apoAI) concentrations were measured by immunoturbid-
ometry with reagents from Incstar (Wokingham, UK).
HDL-C was measured using polyethylene glycol 8000
and enzymatic colorimetry on the sample of plasma taken
at year 6 [29].
2.3. DNA extraction and genotyping
DNA was extracted by the salting-out method [30]. All
PCRs were performed using an MJ Research PTC-225
Peltier Thermal Cycler, in a 20-Al reaction volume using
1 KCl buffer containing 50 mM KCl, 10 mM Tris (pH
8.3), 0.001% gelatin and 0.2 mM each dNTP. PON1 L55M
(sometimes referred to as L54M [31]) was determined
using the conditions of Humbert et al. [11], with an
annealing temperature of 58 jC and 1.5 mM MgCl2.
Digestion was performed using Hsp92II (Promega, Madi-
son) resulting in a 170-bp undigested fragment for the L
allele and 130- and 40-bp fragments for the M allele. For
the PON1 Q192R polymorphism, primers were designed
as follows: 5V-GTGTGTATGTTTTAATTGCAGTTTGA-3V
and 5V-AGTAGACAACATACGACCACGCTA-3V. An
annealing temperature of 58 jC was used and 2.0 mM
MgCl2. Digestion with AlwI (New England Biolabs, Cam-
bridge) resulted in 76- and 70-bp fragments for the Q
allele and 70-, 48- and 28-bp fragments for the R allele.
PON2 S311C polymorphism was determined according to
Sanghera et al. [22]. Digestion of the PCR product by
DdeI (New England Biolabs) resulted in fragments of 120,
75 and 65 bp for the S allele and fragments of 142 and
120 bp for the C allele. Digested products of the L55M
and Q192R polymorphisms were separated on 7.5%
MADGE [32], while the PON2 S311C was separated on
a 9% MADGE. All primers were obtained from Invitrogen.
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database and primers were designed to span both poly-
morphisms, the forward sequence was 5V-TCCAGG-
CATGCCAAACTTT-3V and the reverse sequence was
5V-TTTCCCTCATTTCCCCCTT-3V. Primers were obtained
from Qiagen. Conditions used were 2.25 mM MgCl2, with
an annealing temperature of 54 jC for 30 cycles. Digestion
recognition sequences were, for the A99A polymorphism
GCGC (HhaI) or RGCGCY (HaeII), thus the G allele
version would be digested by the enzyme. For the D107N
polymorphism the recognition site was TTAA (MseI),
resulting in digestion in the presence of the A (Asp).
Samples were amplified by PCR and 8 Al of PCR product
was digested with 5 Al of digest mix containing 2 units of
HhaI, or 2 units of MseI, in separate reactions. In the case
of the A99A digest, a GG homozygote resulted in 112-,
63- and 22-bp fragments, the AA homozygote in 175- and
22-bp fragments and the GA heterozygote in 175-, 112-,
63- and 22-bp fragments. These were detected on a 7.5%
MADGE. For the D107N, two fragments of 120 and 77 bp
were predicted for the GG homozygote, three fragments of
105, 77 and 15 bp for the AA homozygote, and for the
GA heterozygote four fragments of 120, 105, 77 and 15
bp. All genotypes were read and cross-checked against the
computer database entry by two observers blind to status.
Discrepancies were resolved by re PCR and analysis; any
samples lacking a genotype had failed to PCR on at least
two occasions.
2.4. Statistical analysis
Statistical analysis was conducted in intercooled STATA
version 7.0 (STATA Co-operation, Texas). The 71 individ-
uals with diabetes at entry to the study were excluded from
all analysis. Deviations from Hardy–Weinberg were con-
sidered using chi-squared tests. Linkage disequilibrium
between variant sites was determined using D [33]. Log-
transformations were conducted for data which were not
normally distributed (body mass index, fibrinogen, apoB,
systolic blood pressure, triglyceride and HDL). For varia-
bles that required log-transformations, geometric means
and approximate S.D.’s are presented. One-way analysis
of variance (or Kruscal–Wallis when appropriate) was
used to assess differences in continuous baseline character-
istics by CHD status, using either the raw values or log-
transformed values as appropriate; there was no evidence
of heteroscedacity between groups, considered via Bar-
tlett’s test. Differences in HDL, apoA1 and fibrinogen
levels by genotype was considered using ANOVA. HDL
was measured at year 6 and apoAI at baseline and there
was strong correlation between these measures (r = 0.51, P
value < 0.0005). Survival analysis with respect to geno-
types was conducted using Cox’s proportional hazards
model, thus allowing for varying follow-up intervals and
censoring due to competing events. For this modelling,
‘failure time’ was taken as the time to the first CHD event.The significance of the parameters in the Cox model was
assessed using the Likelihood Ratio (LR) Test; 95%
Confidence Intervals (CI) for the estimates were calculated
from the standard errors assuming a normal distribution.
All results were exponentiated and are presented as hazard
ratios (HR) with their corresponding 95% CI. Survival
analysis was adjusted for age by including the term in the
model and differences in the baseline hazard by practice
were permitted (using the strata option in STATA); adjust-
ments for covariates were made by including them in the
model. For all genotypes, individuals homozygous and
carrying the rare allele were grouped for comparison of
combined genotype effects; this was an a priori decision
based on maintaining adequate sample size. Interactions
were primarily considered as deviations from multiplica-
tive effects in the survival model. The relative excess risk
due to interaction (RERI) was used as a measure of
deviation from additive effects and was calculated as:
relative risk (combined genotype effect) relative risk
(effect of PON1 only) relative risk (PON2 only) + 1. A
value of 0 represents no deviation from additive effects,
and 95% CI were calculated using bootstrapping [34].
Survival probability was examined graphically using a
Kaplan–Meier plot. Haplotypes were estimated using
PHASE [35]; individuals were only included in later
analysis of haplotypes if their phase calls were made with
greater than 0.9 probability. In all cases, a P value of
< 0.05 was considered statistically significant. Power cal-
culations were performed, and based on previous genotype
frequency estimates and the 205 CHD events, the study
has 80% power to detect a risk of 1.52 in PON1 55 M
carriers, 1.51 in PON1 192R carriers, and 1.61 in PON2
311 C carriers (P= 0.05).3. Results
3.1. Characteristics of the study group
The NPHSII (Northwick Park Heart Study II) study
consists of healthy middle-aged Caucasian UK males,
2702 of whom were included in the analysis based on
the fact that there was genotype data for at least one of the
polymorphisms of interest. Baseline clinical and biochem-
ical characteristics of the men are summarised in Table 1,
divided on the basis of whether they had suffered a CHD
event or were event-free. The classical risk factors for
CHD show a significant difference between those individ-
uals who have remained healthy and those who have had
an event. In the CHD group, there was a higher percentage
of current smokers (P < 0.0005), and body mass index and
systolic blood pressure were significantly higher. Choles-
terol, triglycerides, apoB, and Lp(a) were higher in the
event group with HDL and apoAI being significantly
lower. Fibrinogen levels were also significantly different
between the groups.
Table 1
Baseline characteristics (meanF S.D.) by CHD event status and genotype frequency
Variable No CHD event n= 2510 CHD event n= 192 P value
Age 56.00 (3.43) 56.56 (3.55) 0.15
Smoking (% current) 27.8% 40.6% < 0.0005
BMIa 26.2 (3.3) 26.8 (3.4) 0.008
Systolic BPa 136.6 (18.7) 141.6 (19.9) 0.0005
Cholesterol 5.71 (1.00) 6.05 (0.99) < 0.00005
Triglyceridea 1.76 (0.92) 2.07 (1.07) < 0.0001
ApoBa 0.86 (0.24) 0.92 (0.22) 0.0001
HDLa 0.80 (0.24) 0.74 (0.20) 0.02
ApoA1 1.64 (0.32) 1.57 (0.27) 0.01
Lp(a)a 8.7 (2.7, 25.5) 12.0 (4.0,28.8) 0.02
Fibrinogena 269.9 (51.5) 283.6 (50.4) 0.0005
Genotype Genotype distribution (11/12/22),
Rare allele freq (95% CI)
Genotype distribution (11/12/22),
Rare allele freq (95% CI)
P values for difference in
Genotype
distribution
Allele
frequency
PON1 L55M 980/982/249 0.34 (0.32, 0.35) 78/71/23 0.34 (0.29, 0.39) 0.60 0.98
Q192R 1219/1000/205 0.29 (0.28, 0.30) 100/69/15 0.27 (0.22, 0.31) 0.56 0.96
PON2 S311C 1307/873/117 0.24 (0.23, 0.25) 109/53/13 0.23 (0.19, 0.28) 0.03 0.96
PON3 A99A 664/1201/588 0.47 (0.47, 0.50) 49/94/47 0.50 (0.44, 0.55) 0.92 0.93
a Distribution of data showed significant deviation from normality, so statistical analysis carried out on ln-transformed data, and geometric means and
approximate S.D.’s are presented.
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Two unvalidated, inferred polymorphisms in the coding
region of PON3 (both in exon 4) were identified from a
search of the database (http://www.ncbi.nlm.nih.gov:80/
LocusLink/). The first polymorphism at amino acid position
99 (rs1053275) is a G -to-A substitution resulting an
synonymous change, Ala (GCG) to Ala (GCA). The second
inferred polymorphism is present at amino acid position 107
(rs2345003) and is also a G-to-A change, predicting a non-
synonymous change from an Asp (GAC) to an Asn (AAC).
Primers were designed to amplify a 197-bp region spanningFig. 1. PON gene cluster linkage disequilibrium analysis. Linkagamino acid positions 99 and 107 using restriction enzyme
digestion to distinguish alleles, HhaI for A99A and MseI for
D107N. One hundred and eighty-six samples from the
NPHSII study were amplified by PCR and digested with
HhaI. In this sample the allele frequencies of the G and A
alleles were found to be 0.51 and 0.49, respectively; this did
not differ significantly from the expected Hardy–Weinberg
proportion. For the MseI digestion, all 186 samples showed
the same digestion pattern of two fragments, 120 and 77 bp
in size, suggesting that no polymorphism is present at this
site. The remaining samples from the NPHSII study were
genotyped only for the A99A polymorphism.e disequilibrium, calculated as delta values, *P < 0.00005.
Table 2
Mean (F S.D.) HDL and apoAI levels by genotypes
Genotype HDL (mmol/l)a P values ApoA1 (mg/l) P values
L55M LL 0.81 (0.25)
n= 716
0.35 1.63 (0.32)
n= 906
0.77
LM 0.80 (0.24)
n= 699
1.63 (0.32)
n= 909
MM 0.78 (0.23)
n= 176
1.65 (0.30)
n= 230
Q192R QQ 0.80 (0.24)
n= 879
0.74 1.63 (0.30)
n= 1132
0.98
QR 0.81 (0.25)
n= 711
1.63 (0.34)
n= 894
RR 0.80 (0.25)
n= 153
1.63 (0.32)
n= 191
S311C SS 0.79 (0.25)
n= 934
0.10 1.63 (0.33)
n= 1194
0.31
SC 0.82 (0.24)
n= 631
1.64 (0.32)
n= 800
CC 0.77 (0.24)
n= 86
1.59 (0.32)
n= 109
A199A2 A1A1 0.80 (0.24)
n= 460
0.78 1.62 (0.32)
n= 592
0.54
A1A2 0.80 (0.24)
n= 885
1.64 (0.32)
n= 1120
A2A2 0.81 (0.25)
n= 426
1.64 (0.33)
n= 546
a Distribution of data showed significant deviation from normality, so
statistical analysis carried out on ln transformed data, and geometric means
and approximate S.D.’s are presented.
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The genotype distribution and frequencies are presented
in Table 1; all were in Hardy–Weinberg equilibrium in
both the CHD event and the event-free groups and allele
frequencies did not differ between the two groups. The
linkage disequilibrium (LD) across the cluster is shown in
Fig. 1. Overall, there was significant LD across the cluster.
PON1 L55M showed negative LD with all the sites and
this was strongest with the Q192R. LD between the PON3Table 3
Risk of CHD by genotype and smoking statusa
Genotype Non
No/event
smokers HR
(95% CI)
L55M LL 735/50 1
LM 760/40 0.76 (0.50, 1.15)
MM 191/13 0.94 (0.51, 1.73)
Q192R QQ 951/62 1
QR 777/38 0.75 (0.50, 1.13)
RR 146/10 1.08 (0.55, 2.11)
S311C SS 1012/65 1
SC 660/30 0.72 (0.47, 1.11)
CC 93/9 1.56 (0.77, 3.14)
A199A2 A1A1 514/31 1
A1A2 923/58 1.07 (0.69, 1.66)
A2A2 450/24 0.93 (0.54, 1.58)
a Adjusted for age and practice.A99A and PON1 and PON2 polymorphisms was also
significant in the whole sample. Using the PHASE haplo-
type assigning programme, it could be deduced that the
frequency of the four halplotypes was 55L-192Q, 0.365;
55L-192R, 0.293; 55M-192Q,0.303; 55M-192R, 0.010;
thus, the 55L allele occurs roughly 55% of the time with
192Q and 45% with 192R, while the 55M allele occurs
with 192Q 97% of the time.
3.4. ApoAI and HDL level association with genotype
The relationship between PON genotypes and HDL
and apoAI levels is presented in Table 2; overall, there
was no significant association detected for any geno-
type. The correlations between HDL-cholesterol and
ApoAI levels in individuals with different PON genotypes
were high (between 0.41 and 0.61, all P < 0.001) but
were not significantly different between groups (data not
shown).
3.5. Genotype and smoking interaction
The possible modifying effect of PON genotype on the
smoking-associated risk of CHD was examined. The
reported number of cigarettes used per week was not
different between genotype groups (all P>0.7). Overall,
in this sample smokers had 1.75-fold (1.31–2.34) higher
risk of CHD compared to non-smokers. As shown in Table
3, compared to PON1 LL non-smokers, in the smokers
only carriers of the M allele, but not LL subjects, had a
higher risk of an event, showing borderline interaction of
smoking and genotype (LM +MM smokers HR = 1.76
(1.17–2.67); P for interaction = 0.09). This effect remained
after adjusting for BMI, blood pressure, cholesterol, HDL-
C and triglyceride level in addition to age and practice
(HR = 1.92, 1.22–3.03). The higher rate of CHD events in
this group is evident in the Kaplan–Meier survival plot
(Fig. 2a). For the Q192R genotype, the smoking-associatedCurrent
No/event
smokers HR
(95% CI)
P value
for interaction
323/28 1.30 (0.81, 2.06) 0.22
293/31 1.64 (1.05, 2.57)
68/10 2.29 (1.16, 4.53)
368/38 1.69 (1.13, 2.53) 0.31
292/31 1.70 (1.10, 2.62)
74/5 1.04 (0.41, 2.59)
404/44 1.71 (1.16, 2.51) 0.89
266/23 1.44 (0.89, 2.33)
39/6 2.66 (1.14, 6.17)
199/18 1.60 (0.89, 2.87) 0.46
372/36 1.69 (1.04, 2.74)
185/23 2.33 (1.30, 3.84)
Fig. 2. Kaplan–Meier survival plots for: (a) smoking and PON1 L55M, adjusted for age and practice, interaction P= 0.003; (b) PON1 L55M and PON2 S311C
genotypes combined, adjusted for age and practice, interaction P= 0.02.
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the smallest group (N = 79) and no strong inference can be
made.
3.6. Combined genotype effect on CHD risk
As shown in Fig. 3, when genotypes were analysed in
pairwise combinations, a significant effect on CHD risk
was found in men homozygous for the PON2 C allele who
also carried the PON1 M allele (LM/MM), who showed
higher CHD risk compared to SS/LL men (OR = 3.54; 95%
CI = 1.81–6.93). Deviation from additive effects of the
genotypes was analysed and greater than additive effectswere confirmed [RERI: 2.67 (0.55, 6.18)]. The data are
presented graphically in Fig. 2b as a survival plot, showing
the higher event rate in this combined genotype group. The
relatively small number of subjects with this genotype
combination (n = 47) precluded an analysis of potential
interaction with smoking, but after adjustment for classical
risk factors, including smoking, the effect remained statis-
tically significant (HR = 4.84(2.42–9.68). No significant
effect on risk was observed for the PON2 S311C and
PON1 Q192R genotype combination.
Haplotype analysis of all four genotypes from the three
PON genes did not identify a risk-associated haplotype (data
not shown). This is partly because of the low numbers of
Fig. 3. Odds ratio for CHD by combined PON1 L55M and PON2 S311C genotypes.
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in only 61% of subjects could a ‘phase call’ be made with
sufficient precision (probability>0.9). These low phase calls
are most likely the result of the weaker LD between PON1
and PON3.4. Discussion
4.1. PON gene variants and CHD risk
The present study of over 2700 healthy middle-aged
men evaluated the association of four polymorphisms in
the PON gene family with the risk of CHD. Although no
single polymorphism was associated with a statistically
significant independent effect on risk, the PON1 L55M,
when considered together with PON2 S311C, did influence
risk of CHD, and the PON1 L55M modified the CHD risk
associated with smoking. Two reported PON3 variants
were examined; one could not be verified and the A99A,
although common, was not associated with any effect on
CHD risk. Although some apparently silent sequence
changes in exons have been reported to influence gene
expression by altering the normal intron–exon splicing
processes (reviewed in Ref. [36]), there is no direct
evidence to suggest that the sequence change in codon
99 is functional, and further SNP detection is required to
examine the potential role of PON3 in detail.
4.2. PON1 and CHD risk
To date, studies that have examined the relationship
between PON1 and PON2 and risk of CHD have in
general been carried out in case-control cohorts. The
NPHSII study comprises a prospective analysis of men
healthy on entry which eliminates any risk of survival
bias affecting the results. The 71 subjects who had
diabetes at baseline were excluded from all follow-upanalysis. This group of individuals was too small to allow
any meaningful statistical comparisons of the impact of
PON genotypes on development of CHD. We did not
confirm the relationship between the L55M and Q192R
polymorphisms and CHD risk seen by others [13]. Power
calculations show that the smallest detectable odds ratio
effect for L55 in NPHSII is 1.52, and since the previously
reported risk estimates were in the range 1.7–1.9 [31,37],
a similarly large risk effect in healthy men is unlikely, but
we cannot rule out a more modest effect. A meta-analysis
of studies performed up until 2001 on the Q192R
genotype demonstrated that there was an overall relative
risk of the R allele of 1.44 (1.17–1.77) [38]. There was,
however, evidence of publication bias with the greatest
effects being seen in the smaller studies. Our study found
no increase in frequency of the 192R allele in CHD in
cases, but power calculations show the smallest detectable
odds ratio in NPHSII with this allele is 1.57, so the
reported modest effects on risk cannot be ruled out. Thus,
in healthy subjects the PON1 polymorphisms may have
little or no effect on risk but when other factors, such as
FH or diabetes [18], are introduced, the impact of the
polymorphisms on CHD risk may become clinically
significant.
4.3. Smoking and PON1 genotype
It has been suggested that the mechanism by which
smoking increases CHD risk may be directly on reducing
PON activity and promoting lipid oxidation. The ability
of PON1 to prevent lipid oxidation, and the fact that
smoking reduces PON activity, implies that variants that
cause low PON activity may play a role in modulating
smoking-associated CHD risk (reviewed in Ref. [39]).
When effects of smoking and genotype on CHD risk
were examined, there was evidence for higher smoking-
associated risk associated in men carrying the PON1 55
M allele, i.e. the LL subjects showed a degree of
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appeared to be co-dominant, but when LM+MM men
were considered together, the interaction term was only of
borderline statistical significance, and this suggestion of
smoking risk-modification by the 55 M allele requires
confirmation in other prospective studies. The lower risk
in the RR individuals could also be attributable to the
lack of MM individuals in this group. Although this is a
possibility, the strong LD between these two sites means
that it is not possible to tease this out with statistical
certainty. It should be noted that if the proportion of
smokers differs among studies, this interaction with
smoking could account for why some of the previous
studies failed to find an association with risk.
4.4. PON2 and CHD risk
Previous reports have identified the PON2 311 C allele as
having a protective role in CHD risk [21,22]. We could not
confirm this but, in contrast, men who carried the PON1 55
M allele and who were PON2 311 C homozygotes were
significantly more likely to develop CHD (OR= 3.54, 95%
CI 1.81–6.83) when compared to other genotype combina-
tions. Since the 55 M allele has been independently asso-
ciated with risk [32], it might have been assumed that the
risk would be moderated if the PON2 311 C allele was
indeed protective. However, the NPHSII data are consistent
with the observation of an increased risk with this combined
genotype in a small case-control study of Korean subjects
[40]. Since there is almost complete allelic association
(LD>0.99) between the C311S and the A148G change
[20], only the C311S variant was genotyped here, but the
effect on risk may be due to either change (or both acting
together), and in vitro studies on functionality will be
required to examine this. The 55 M isoform has been shown
to be less stable than the 55 L isoform, which may indicate a
mechanism of action [41], although since the 55 M allele is
in linkage disequilibrium with the potentially functional –
108T allele [42], the mechanism may alternatively be
through effects on transcriptional control of PON1 synthe-
sis. Another study identified an increased risk in individuals
who were carriers of the 192R allele and the 311S allele
[22], but no such effect was seen in the present study.
4.5. PON activity rather than genotype is a better risk
marker
The unavailability of plasma measures of PON1 activity
is a limitation of this study. It has been reported that PON
activity and mass is a more important marker for CHD risk
than genotype [38] although the activity of PON is, at least
in part, related to genotype [43]. There are, as yet, no
standard assays to assess the levels of PON2 and PON3,
and it is currently unclear as to the relative usefulness of
measures of PON activity against different synthetic sub-
strates, or of PON antigen levels, in determining CHD risk.It is likely that the levels of PON would be more important
in risk determination than PON genotypes alone, or that the
combination of phenotype and genotype may give a better
risk estimate.
4.6. PON activity and anti-oxidant potential
Although PON1 (and PON3) are found in the plasma
associated with HDL particles [44], the role of PON2 in
vivo is unclear, and while the different substrates of PON1
are well studied, little is known for PON2. PON2 is
ubiquitously expressed and is not detectable on either
HDL or LDL. It is found in all of the cells associated with
the artery wall, as well as in primary macrophages where
neither PON1 nor PON3 are found, and has been described
as a cellular antioxidant due to its ability to reduce the
intracellular oxidative stress levels [45]. PON1 has a num-
ber of conserved cysteine residues, the one at position 284
being required for protection of LDL from oxidation [46].
The direct effect of the S311C variant on PON2 activity has
not been reported but it may be that the introduction of a
cysteine at position 311 in the PON2 gene is having an
important physical effect. Further studies into the action of
PON2 need to be performed in order to explain this finding.
PON2 and PON3 show no paraoxon hydrolytic activity and
it has been suggested that it is lactonase activity, rather than
arylesterase or organophosphate activity, that is the common
feature of the PONs. This has lead to the mechanism of
protection being postulated to be the hydrolysis of a
potentially toxic endogenous lactone, which would other-
wise produce vascular damage [44]. Whatever the actual
physiological role of the PONs, their anti-oxidant ability in
vitro has been proven beyond doubt.
4.7. PON gene cluster and CHD risk
The three PON genes lie within a 136-kb region of
chromosome 7, and the frequency and linkage disequilibri-
um between the PON1 and PON2 polymorphisms was in
agreement with the those previously published [23]. Link-
age disequilibrium between the PON3 polymorphism and
the PON1 and PON2 alleles was significant. LD estimates
in NPHSII were similar to those reported in previous
Caucasian samples, although it has been suggested that
there may be differences in linkage disequilibrium among
populations [40]. Since PON1, PON2 and PON3 are closely
linked, it could be that a variant in any of these genes may
be in allelic association with a functional change elsewhere,
and that they merely act as markers for this change, i.e. with
an as yet unidentified polymorphism in PON3 or, indeed,
another closely linked gene. Several polymorphisms in
the promoter region of the PON1 gene have been identi-
fied [47,48] and some studies indicate a relationship be-
tween these polymorphisms and CHD [49,50]. One study
suggested that the  108C>T promoter polymorphism
accounted for much of the risk effect seen with the L55M
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using different methods, accurate genotyping for this site
could not be obtained on NPHSII DNA (unpublished).
Haplotype analysis might be useful over short regions of
single PON1 genes such as the promoter region and the
exons including the L55M and Q192R amino acid changes
in the PON1 gene.
Overall, the data suggest that, in combination, the
PON1 protein found in HDL and PON2 found in arterial
cells are playing an important role in protection against
CHD. Polymorphisms within the PON genes may affect
the ability of the PON proteins to exert their antioxidant
effects. However, the NPHSII data suggest that this is not
due to one polymorphism alone, and may be mediated by
external factors such as smoking. This highlights the need
for the study of multiple polymorphic sites, in combination
with evaluation of environmental factors, to elucidate the
genetic contribution of the paraoxonases and risk of CHD.
Future studies should make use of protocols that would
provide information on PON levels as well as further SNP
characterisation. Taken together, these data may provide a
more accurate prediction of PON1 levels and allow an
assessment of genetic polymorphism and activity levels on
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